Astellas farms out third molecule to Drais
This article was originally published in Scrip
Astellas is licensing out its third molecule in a year to a company affiliated with the US venture Drais Pharmaceuticals, in the continuing pursuit of a "multi-track" R&D strategy that allows the continued development of promising projects while sharing costs.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.